Stout Advises on Sale of Rev1 to Asahi

July 22, 2021

Stout announced today that its client, Rev 1 Engineering, Inc. (“Rev1”), has been acquired by Asahi Intecc Co., Ltd (“Asahi”), a global leader in medical device development, manufacturing, and sales. Stout served as exclusive financial advisor to Rev1 in connection with this transaction.

Founded in 2008 and headquartered in Murrieta, CA, Rev1 is a cutting-edge outsourced medical device design and engineering firm offering a variety of services, including First of Kind product development, prototype development, design for manufacturing, and product design improvement for next generation devices. The company’s experience spans a wide range of medical device industry sub-segments, including: electroporation; drug/device combination products; structural heart, diagnostic, and interventional catheters; balloons and stent delivery and anchoring systems; neuromodulation; gene therapy delivery; wound closure; and more. The company prides itself on its ability to help customers accelerate time to market, including startups looking for external resources to grow and large OEMs selling devices around the world.

“Stout ran a broad global process to vet the ideal partner and achieve an optimal outcome for our founders and employees,” said Eric Johnson, Co-Founder of Rev1. “Asahi has a leading market position and complementary technology expertise in interventional vascular devices, which is expected to accelerate our future growth.”

“Stout did a great job of managing through the deal stages, negotiations, and complexities of a cross-border transaction,” added Phil Burke, Co-Founder of Rev1. “We are very excited to be working with the Asahi team, who we have enjoyed strategizing with and getting to know during the process. We look forward to working together with them to grow the Asahi family of businesses.”

“Asahi offers Rev1 access to large new project opportunities and the possibility of providing end-to-end solutions to many of the leading medical device manufacturers worldwide,” said John Calcagnini, Managing Director and Head of Stout’s Healthcare and Life Sciences Investment Banking practice.

John led the transaction, and Stout’s Alec Wittenberg assisted in executing the deal. Paul Hastings served as deal counsel to Rev1.

Asahi is a leading global medical device developer, manufacturer and seller of guide wires, guide catheters, and balloon dilatation catheters, which are used in interventional vascular procedures. The company is listed on the first section of the Tokyo Stock Exchange.

See more information on our Investment Banking services.